Growth hormone secretagogue
CJC-1295
GHRH analog
Not approved — trial failures, now restricted
Based on expert consensus from publicly available videos plus public FDA/regulatory status — not medical advice. Peptides are prescription territory; consult a physician before using anything here.
The Verdict
A GH-releasing peptide with clinical-trial failures behind it and a fresh FDA restriction — Huberman covers the safety concerns. Hype outruns the evidence here.
The Evidence
FDA / Legal Status
Not FDA-approved; moved to FDA 'Category 2' (restricts compounding)
Human Evidence
Huberman notes clinical-trial failures and safety concerns; an adverse anecdote of eliminated REM sleep
Sport / Doping
Banned in sport
Safety Flags
- Trial failures and safety concerns; FDA Category-2 restricted
- GH-elevation cancer risk; reported REM-sleep disruption
Who Covers It
Other experts in the panel had no substantive coverage of this peptide — we don't guess their position.
Want the deep dive on CJC-1295?
This grade is free. Pro unlocks chat with the full expert dataset — ask about dosing, stacks, sourcing, and the exact citations behind every claim.
Cancel anytime